Back to results
US 2014/0005249 A1Published application
Nkx2.2 inhibitors as drugs
AssigneesUniversite Montpellier 2 Sciences Et Techniques, Centre National De La Recherche Scientifique, Centre Hospitalier Universitaire De Montpellier, Institut Curie
InventorsJean-Philippe Hugnot, Pierre-Olivier Guichet, Marisa Teigell, Ivan Bieche, Rosette Lidereau, Dominique Joubert, Luc Bauchet, Valerie Rigau
Life of this patent
Estimating the term…
Abstract
The present invention relates to NKX2.2 inhibitors such as shRNAs for treating pathologies.
Claims11
1-12. (canceled)
A method for treating central nervous system (CNS) tumors and gastro-entero-pancreatic neuroendocrine (GEP NE) tumors expressing NKX2.2, in a patient in a need thereof, comprising the administration of a pharmaceutically effective amount of a product inhibiting
- a. the expression of the gene coding for the NKX2.2 protein, and/or
- b. the activity of the NKX2.2 protein.
Dependencies are inferred from the claim text.